Relief Therapeutics (RLF:SIX) startet FDA-Studie mit Aviptadil an der University of Miami zur Behandlung von COVID-19-induzierter Atemnot
von , Uhr
GENF--(BUSINESS WIRE)--Relief Therapeutics drug Aviptadil enters FDA trial at University of Miami, to treat COVID-19-induced Respiratory Distress
